Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents
Status: Enrolling
Updated:  1/23/2013
Children's Hospital of Richmond, VA
mi
from
Richmond, VA
A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents
Status: Enrolling
Updated: 1/23/2013
Children's Hospital of Richmond, VA
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects
A Phase I, Open Label, Randomized, Four-Period Crossover Study to Evaluate the Effects of Calcium Carbonate 1200 mg and Ferrous Fumarate 324 mg on Pharmacokinetics of Dolutegravir 50 mg in Healthy Adult Subjects
Status: Enrolling
Updated:  1/24/2013
GSK Investigational Site
mi
from
Westwood, KA
A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects
A Phase I, Open Label, Randomized, Four-Period Crossover Study to Evaluate the Effects of Calcium Carbonate 1200 mg and Ferrous Fumarate 324 mg on Pharmacokinetics of Dolutegravir 50 mg in Healthy Adult Subjects
Status: Enrolling
Updated: 1/24/2013
GSK Investigational Site
mi
from
Westwood, KA
Click here to add this to my saved trials
A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects
A Single-Center Randomized, Open-Label, Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 LAP in Healthy Adult Subjects.
Status: Enrolling
Updated:  1/31/2013
GSK Investigational Site
mi
from
Westwood, KA
A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects
A Single-Center Randomized, Open-Label, Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 LAP in Healthy Adult Subjects.
Status: Enrolling
Updated: 1/31/2013
GSK Investigational Site
mi
from
Westwood, KA
Click here to add this to my saved trials
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Re-boosting Study With Vacc-4x in Subjects Infected With HIV-1 Who Have Maintained an Adequate Response to ART
Status: Enrolling
Updated:  2/6/2013
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Re-boosting Study With Vacc-4x in Subjects Infected With HIV-1 Who Have Maintained an Adequate Response to ART
Status: Enrolling
Updated: 2/6/2013
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Re-boosting Study With Vacc-4x in Subjects Infected With HIV-1 Who Have Maintained an Adequate Response to ART
Status: Enrolling
Updated:  2/6/2013
UCLA Care Center
mi
from
Los Angeles, CA
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Re-boosting Study With Vacc-4x in Subjects Infected With HIV-1 Who Have Maintained an Adequate Response to ART
Status: Enrolling
Updated: 2/6/2013
UCLA Care Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Re-boosting Study With Vacc-4x in Subjects Infected With HIV-1 Who Have Maintained an Adequate Response to ART
Status: Enrolling
Updated:  2/6/2013
UC Davis Medical Center
mi
from
Sacramento, CA
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Re-boosting Study With Vacc-4x in Subjects Infected With HIV-1 Who Have Maintained an Adequate Response to ART
Status: Enrolling
Updated: 2/6/2013
UC Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults
Pilot Study of Extended-release Exenatide to Improve Glucose Control and Reduce Systemic Inflammation in Diabetic, HIV-infected Adults on Antiretroviral Therapy
Status: Enrolling
Updated:  2/13/2013
Vanderbilt University
mi
from
Nashville, TN
Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults
Pilot Study of Extended-release Exenatide to Improve Glucose Control and Reduce Systemic Inflammation in Diabetic, HIV-infected Adults on Antiretroviral Therapy
Status: Enrolling
Updated: 2/13/2013
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated:  2/26/2013
Kaiser Permanente Infectious Diseases, Antelope Valley
mi
from
Lancaster, CA
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated: 2/26/2013
Kaiser Permanente Infectious Diseases, Antelope Valley
mi
from
Lancaster, CA
Click here to add this to my saved trials
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated:  2/26/2013
Veterans Administration Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated: 2/26/2013
Veterans Administration Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated:  2/26/2013
University of California, Los Angeles, School of Medicine
mi
from
Los Angeles, CA
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated: 2/26/2013
University of California, Los Angeles, School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated:  2/26/2013
AIDS Healthcare Foundation
mi
from
Los Angeles, CA
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated: 2/26/2013
AIDS Healthcare Foundation
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV
Pilot Study to Assess Gut Mucosal B Cells in Individuals Co-Infected With HCV and HIV
Status: Enrolling
Updated:  2/28/2013
Rockefeller University
mi
from
New York, NY
Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV
Pilot Study to Assess Gut Mucosal B Cells in Individuals Co-Infected With HCV and HIV
Status: Enrolling
Updated: 2/28/2013
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV
A Phase IV Open-label Evaluation of Safety, Tolerability and Patient Acceptance of Atazanavir Boosted With Ritonavir Combined With a Fixed-dose Formulation of Tenofovir DF and Emtricitabine for Non-occupational Prophylaxis Following Potential Exposure to HIV-1
Status: Enrolling
Updated:  3/6/2013
Fenway Health
mi
from
Boston, MA
Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV
A Phase IV Open-label Evaluation of Safety, Tolerability and Patient Acceptance of Atazanavir Boosted With Ritonavir Combined With a Fixed-dose Formulation of Tenofovir DF and Emtricitabine for Non-occupational Prophylaxis Following Potential Exposure to HIV-1
Status: Enrolling
Updated: 3/6/2013
Fenway Health
mi
from
Boston, MA
Click here to add this to my saved trials
Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV
HBV Prevention for Homeless at Risk for HBV/HCV/HIV
Status: Enrolling
Updated:  4/5/2013
Friends Community Center
mi
from
Los Angeles, CA
Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV
HBV Prevention for Homeless at Risk for HBV/HCV/HIV
Status: Enrolling
Updated: 4/5/2013
Friends Community Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  4/9/2013
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 4/9/2013
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  4/9/2013
IMMUNOe International Research Centers
mi
from
Southwest Arapahoe, CO
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 4/9/2013
IMMUNOe International Research Centers
mi
from
Southwest Arapahoe, CO
Click here to add this to my saved trials
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  4/9/2013
Joe DiMaggio Children's Hospital
mi
from
Hollywood, FL
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 4/9/2013
Joe DiMaggio Children's Hospital
mi
from
Hollywood, FL
Click here to add this to my saved trials
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  4/9/2013
University of Iowa Hospitals & Clinic
mi
from
Iowa City, IA
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 4/9/2013
University of Iowa Hospitals & Clinic
mi
from
Iowa City, IA
Click here to add this to my saved trials
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  4/9/2013
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 4/9/2013
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)
Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)
Status: Enrolling
Updated:  4/15/2013
UAB
mi
from
Birmingham, AL
Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)
Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)
Status: Enrolling
Updated: 4/15/2013
UAB
mi
from
Birmingham, AL
Click here to add this to my saved trials
Subclinical Atherosclerosis in HIV-infected Patients
Subclinical Atherosclerosis in HIV-infected Patients
Status: Enrolling
Updated:  5/1/2013
Massachusetts General Hospital
mi
from
Boston, MA
Subclinical Atherosclerosis in HIV-infected Patients
Subclinical Atherosclerosis in HIV-infected Patients
Status: Enrolling
Updated: 5/1/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated:  5/4/2013
Alaska Native Tribal Health Consortium
mi
from
Anchorage, AK
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated: 5/4/2013
Alaska Native Tribal Health Consortium
mi
from
Anchorage, AK
Click here to add this to my saved trials
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated:  5/4/2013
Inter Tribal Council of Arizona, Inc.
mi
from
Phoenix, AZ
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated: 5/4/2013
Inter Tribal Council of Arizona, Inc.
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated:  5/4/2013
Northwest Portland Area Indian Health Board
mi
from
Portland, OR
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated: 5/4/2013
Northwest Portland Area Indian Health Board
mi
from
Portland, OR
Click here to add this to my saved trials
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated:  5/4/2013
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated: 5/4/2013
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Continued Access to DRV/Rtv in HIV-1 Infected Children and Adolescents (Rollover Patients From C212, C228, C230)
Status: Enrolling
Updated:  5/6/2013
Clinical Research Facility
mi
from
Chattanooga, TN
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
Continued Access to DRV/Rtv in HIV-1 Infected Children and Adolescents (Rollover Patients From C212, C228, C230)
Status: Enrolling
Updated: 5/6/2013
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Project TEACH-Kenya
Project Tailoring Effective And Community-based HIV Interventions in Kenya
Status: Enrolling
Updated:  5/8/2013
Albert Einstein College of Medicine
mi
from
Bronx, NY
Project TEACH-Kenya
Project Tailoring Effective And Community-based HIV Interventions in Kenya
Status: Enrolling
Updated: 5/8/2013
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Evaluation of Barriers to Postpartum Care in HIV Infected Women
Evaluation of Barriers to Postpartum Care in HIV Infected Women
Status: Enrolling
Updated:  5/10/2013
Harris County Hospital District Clinics-Thomas Street Clinic, Northwest Clinic
mi
from
Houston, TX
Evaluation of Barriers to Postpartum Care in HIV Infected Women
Evaluation of Barriers to Postpartum Care in HIV Infected Women
Status: Enrolling
Updated: 5/10/2013
Harris County Hospital District Clinics-Thomas Street Clinic, Northwest Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluation of Barriers to Postpartum Care in HIV Infected Women
Evaluation of Barriers to Postpartum Care in HIV Infected Women
Status: Enrolling
Updated:  5/10/2013
Harris County Hospital District Clinics-LBJ hospital
mi
from
Houston, TX
Evaluation of Barriers to Postpartum Care in HIV Infected Women
Evaluation of Barriers to Postpartum Care in HIV Infected Women
Status: Enrolling
Updated: 5/10/2013
Harris County Hospital District Clinics-LBJ hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Intervention for (Those) Recently Informed of Seropositive Status (IRISS)
A Positive Affect Intervention for Those Recently Diagnosed With HIV
Status: Enrolling
Updated:  5/16/2013
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Intervention for (Those) Recently Informed of Seropositive Status (IRISS)
A Positive Affect Intervention for Those Recently Diagnosed With HIV
Status: Enrolling
Updated: 5/16/2013
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Local Institution
mi
from
Phoenix, AZ
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Local Institution
mi
from
Phoenix, AZ
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Lac & Usc Medical Center
mi
from
Los Angeles, CA
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Lac & Usc Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Local Institution
mi
from
Washington,
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Local Institution
mi
from
Washington,
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Children'S Diagnostic Treatment Center
mi
from
Fort Lauderdale, FL
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Children'S Diagnostic Treatment Center
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Arnold Palmer Hospital For Children And Woman
mi
from
Orlando, FL
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Arnold Palmer Hospital For Children And Woman
mi
from
Orlando, FL
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Cleveland Clinic Florida
mi
from
Weston, FL
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
University of Chicago
mi
from
Chicago, IL
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Lsu Health Sciences Center
mi
from
New Orleans, LA
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Lsu Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Children's Hospital
mi
from
Boston, MA
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Univ of Massachusetts Med School
mi
from
Worcester, MA
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Univ of Massachusetts Med School
mi
from
Worcester, MA
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
The Wellness Center
mi
from
Las Vegas, NV
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
The Wellness Center
mi
from
Las Vegas, NV
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
UMDNJ-New Jersey Medical School
mi
from
Newark, NJ
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
UMDNJ-New Jersey Medical School
mi
from
Newark, NJ
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Montefiore Medical Center/Aecom
mi
from
Bronx, NY
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Montefiore Medical Center/Aecom
mi
from
Bronx, NY
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Bronx Municipal Hospital Center
mi
from
Bronx, NY
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Bronx Municipal Hospital Center
mi
from
Bronx, NY
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Schneider'S Childrens Hospital
mi
from
New Hyde Park, NY
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Schneider'S Childrens Hospital
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Harlem Hospital Center
mi
from
New York, NY
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Harlem Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Office Of John Montana
mi
from
New York, NY
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Office Of John Montana
mi
from
New York, NY
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
St Luke's - Roosevelt Hospital Center
mi
from
New York, NY
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
St Luke's - Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Women And Childrens Care Center
mi
from
New York, NY
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Women And Childrens Care Center
mi
from
New York, NY
Click here to add this to my saved trials